MILAN, Italy, August 24 /PRNewswire/ --

- Eurand Invites Public to Listen to Webcast

Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that
develops enhanced pharmaceutical and biopharmaceutical products based on its
proprietary drug formulation technologies, is scheduled to present at the
Thomas Weisel Partners Healthcare Conference in Boston, Massachusetts on
Wednesday, September 5, 2007.

Gearoid Faherty, Eurand's Chief Executive Officer, is scheduled to speak
to conference attendees at 10:55 am Eastern Daylight Time (4:55 pm Central
European Summer Time). A live audio webcast of this event will be available
to the general public by visiting Eurand's website at www.eurand.com.
Following the live webcast, an archived version of the call will be available
at the same website.

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced
pharmaceutical and biopharmaceutical products based on its proprietary drug
formulation technologies. Eurand has had four products approved by the FDA
since 2000 and has a pipeline of product candidates in development for itself
and its collaboration partners. Eurand has completed two phase III clinical
trials on its lead product candidate, Zentase(TM), for the treatment of
Exocrine Pancreatic Insufficiency and filed the first segment of its rolling
NDA for this product in June 2007. Eurand's technology platforms include
bioavailability enhancement of poorly soluble drugs, customized release,
taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements. Such
forward-looking statements include those which express plan, anticipation,
intent, contingency, goals, targets or future development and/or otherwise
are not statements of historical fact including, but not limited to our plans
for our NDA filing, enrollment and future plans for our clinical trials,
progress of and reports of results from clinical studies, clinical
development plans and product development activities. The words
"potentially", "could", "calls for" and similar expressions also identify
forward-looking statements. These statements are based upon management's
current expectations and are subject to risks and uncertainties, known and
unknown, which could cause actual results and developments to differ
materially from those expressed or implied in such statements. Factors that
could affect actual results include risks associated with the possibility
that the FDA refuses to approve our NDA; the outcome of any discussions with
the FDA; and unexpected delays in preparation of materials for submission to
the FDA as a part of our NDA filing. Forward-looking statements contained in
this press release are made as of this date, and we undertake no obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise. Actual events could differ
materially from those anticipated in the forward-looking statements.

CONTACTS:

    Marian Cutler                       Nick Laudico/Elizabeth Scott
    Vice President,                     The Ruth Group
    Corporate Communications            +1-646-536-7030 / 7014
    Eurand                              nlaudico@theruthgroup.com
    +1-267-759-9324                     escott@theruthgroup.com
    Marian.Cutler@eurand.com

Web site: http://www.eurand.com